PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 3, 2024Journal of Clinical Oncology26 citations

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

View Full Paper
WXWenxin XuVGValérie GaborieauSNSamuel M. Niman

Key Points

Key points are not available for this paper at this time.

Abstract

PURPOSE Both clear cell and papillary renal cell carcinomas (RCCs) overexpress kidney injury molecule-1 (KIM-1). We investigated whether plasma KIM-1 (pKIM-1) may be a useful risk stratification tool among patients with suspicious renal masses. METHODS Prenephrectomy pKIM-1 was measured in two independent cohorts of patients with renal masses. Cohort 1, from the prospective K2 trial, included 162 patients found to have clear cell RCC (cases) and 162 patients with benign renal masses (controls). Cohort 2 included 247 patients with small (cT1a) renal masses from an academic biorepository, of whom 184 had RCC. We assessed the relationship between pKIM-1, surgical pathology, and clinical outcomes. RESULTS In Cohort 1, pKIM-1 distinguished RCC versus benign masses with area under the receiver operating curve (AUC-ROC, 0.81 95% CI, 0.76 to 0.86). In Cohort 2 (cT1a only), pKIM-1 distinguished RCC versus benign masses (AUC-ROC, 0.74 95% CI, 0.67 to 0.80) and the addition of pKIM-1 to an established nomogram for predicting malignancy improved the model AUC-ROC (0.65 95% CI, 0.57 to 0.74 v 0.78 95% CI, 0.72 to 0.85). A pKIM-1 cutpoint identified using Cohort 2 demonstrated sensitivity of 92.5% and specificity of 60% for identifying RCC in Cohort 1. In long-term follow-up of RCC cases (Cohort 1), higher prenephrectomy pKIM-1 was associated with worse metastasis-free survival (multivariable MFS hazard ratio HR 1.29 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.53) and overall survival (multivariable OS HR 1.31 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.54). In long-term follow-up of Cohort 2, no metastatic events occurred, consistent with the favorable prognosis of resected cT1a RCC. CONCLUSION Among patients with renal masses, pKIM-1 is associated with malignant pathology, worse MFS, and risk of death. pKIM-1 may be useful for selecting patients with renal masses for intervention versus surveillance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xu et al. (2024) studied this question.

synapsesocial.com/papers/68e6b93cb6db64358763a722https://doi.org/10.1200/jco.23.00699
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnostic utility of plasma and urine KIM-1 levels in clear cell renal cell carcinoma: an observational prospective study2026
  2. 2KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma2026 · 3 citations
  3. 3KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.2026 · 1 citations
  4. 4Kidney injury molecule‐1 (KIM-1) in localized and metastatic renal cell carcinoma (RCC): A meta-analysis and systematic review.2026
  5. 5Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma2025 · 35 citations